Tatsuzo Mishina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tatsuzo Mishina has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Arata Ishii
Department of Hematology Chiba University Hospital Chiba Japan
2 shared publications- Chiaki Nakaseko
Department of Hematology, International University of Health and Welfare, Narita, Japan
2 shared publications - Shokichi Tsukamoto
Department of Hematology, Chiba University Hospital, Chiba, Japan
2 shared publications Chika Manako
Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan
1 shared publicationChikako Ohwada
Department of Hematology Chiba University Hospital Chiba Japan
1 shared publication- Chikako Ohwada
Department of Hematology, Chiba University Hospital, Chiba, Japan
1 shared publication
Latest Publications
- 15 October 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (2) , 208-214
Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has a poor prognosis, particularly in patients ineligible for autologous stem cell transplantation or cellular immunotherapy. This study evaluated the effectiveness of polatuzumab vedotin combined with rituximab and bendamustine (PBR) therapy in comparison to conventional chemotherapy in patients with R/R DLBCL. Of 86 patients with first relapse or primary refractory DLBCL, 32 received PBR in any subsequent line, while 54 received conventional chemotherapy alone. For comparison, 32 baseline-matched patients were selected from these 54 and defined as the conventional chemotherapy group. The median overall survival (OS) for all patients was 17.3 months (range, 1.5–85.7 months), with the PBR-treated group showing significantly improved outcomes (median OS 19.7 vs. 15.8 months, P = 0.025). Univariate and multivariate analyses identified PBR as a favorable prognostic factor for OS. In the second-line setting, 41.2% of patients who received PBR were ≥ 80 years, compared with just 11.1% of those who received salvage regimens. Despite this older age distribution, the PBR group showed a trend toward favorable progression-free survival. These results suggest that PBR therapy is more effective and tolerable than conventional chemotherapy in patients with R/R DLBCL.
- 15 October 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (2) , 208-214
Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has a poor prognosis, particularly in patients ineligible for autologous stem cell transplantation or cellular immunotherapy. This study evaluated the effectiveness of polatuzumab vedotin combined with rituximab and bendamustine (PBR) therapy in comparison to conventional chemotherapy in patients with R/R DLBCL. Of 86 patients with first relapse or primary refractory DLBCL, 32 received PBR in any subsequent line, while 54 received conventional chemotherapy alone. For comparison, 32 baseline-matched patients were selected from these 54 and defined as the conventional chemotherapy group. The median overall survival (OS) for all patients was 17.3 months (range, 1.5–85.7 months), with the PBR-treated group showing significantly improved outcomes (median OS 19.7 vs. 15.8 months, P = 0.025). Univariate and multivariate analyses identified PBR as a favorable prognostic factor for OS. In the second-line setting, 41.2% of patients who received PBR were ≥ 80 years, compared with just 11.1% of those who received salvage regimens. Despite this older age distribution, the PBR group showed a trend toward favorable progression-free survival. These results suggest that PBR therapy is more effective and tolerable than conventional chemotherapy in patients with R/R DLBCL.
- 11 January 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (1) , e70037
Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients
POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features. Clinical data and bone lesion information by computed tomography (CT) imaging were obtained from the 114 patients with POEMS syndrome. Regardless of the presence of sclerotic bone lesions, patients were divided into two groups according to the presence (lytic group: n = 17, 14.9%) or absence (non‐lytic group: n = 97, 85.1%) of osteolytic lesions. In the lytic group, several patients were histologically diagnosed with plasmacytoma. In the evaluation by CT imaging, osteolytic lesions had a higher response rate than sclerotic lesions (75.0% vs. 42.2%, p = 0.079). Nevertheless, patients in lytic group showed earlier clinical progression than patients in non‐lytic group (2‐year progression‐free survival, 66.7% vs. 90.2%, p = 0.069). The presence of innumerable bone lesions was an independent poor prognostic factor in multivariate analysis, regardless of the presence of osteolytic lesions (hazard ratio, 3.4; 95% confidence interval 1.1–10.9; p = 0.040). Osteolytic and innumerable bone lesions are potential prognostic factors. Further studies involving histopathological evaluations of bone lesions are warranted.
- 11 January 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (1) , e70037
Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients
POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features. Clinical data and bone lesion information by computed tomography (CT) imaging were obtained from the 114 patients with POEMS syndrome. Regardless of the presence of sclerotic bone lesions, patients were divided into two groups according to the presence (lytic group: n = 17, 14.9%) or absence (non‐lytic group: n = 97, 85.1%) of osteolytic lesions. In the lytic group, several patients were histologically diagnosed with plasmacytoma. In the evaluation by CT imaging, osteolytic lesions had a higher response rate than sclerotic lesions (75.0% vs. 42.2%, p = 0.079). Nevertheless, patients in lytic group showed earlier clinical progression than patients in non‐lytic group (2‐year progression‐free survival, 66.7% vs. 90.2%, p = 0.069). The presence of innumerable bone lesions was an independent poor prognostic factor in multivariate analysis, regardless of the presence of osteolytic lesions (hazard ratio, 3.4; 95% confidence interval 1.1–10.9; p = 0.040). Osteolytic and innumerable bone lesions are potential prognostic factors. Further studies involving histopathological evaluations of bone lesions are warranted.
- Open Access
- 29 October 2021
- Published by Elsevier in Leukemia Research Reports
- Vol. 16, 100278
Successful allogeneic bone marrow transplantation after massive gastrointestinal bleeding in a patient with myelodysplastic syndrome associated with intestinal Behçet-like disease
- 29 October 2021
- Published by Elsevier in Leukemia Research Reports
- Vol. 16, 100278
Open AccessSuccessful allogeneic bone marrow transplantation after massive gastrointestinal bleeding in a patient with myelodysplastic syndrome associated with intestinal Behçet-like disease